Related Experiment Video
Updated: May 2, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
A summary of the iodine supplementation study protocol (I2S2): a UK multicentre randomised controlled trial in
Fiona Williams1, Robert Hume, Simon Ogston
1Population Health Sciences, Medical Research Institute, University of Dundee, Dundee, UK.
Insights
This study investigated if iodine supplementation improves neurodevelopment in preterm infants. Researchers aimed to determine if addressing iodine deficiency in parenteral nutrition benefits infant brain development.
Area of Science:
- Neonatal Medicine
- Nutritional Science
- Developmental Neuroscience
Background:
- Iodine is crucial for thyroxine synthesis, essential for fetal and early childhood brain development.
- Preterm infants often receive prolonged parenteral nutrition, increasing risk of iodine deficiency.
- Standard parenteral nutrition solutions may not provide adequate iodine, leading to potential insufficiency.
Purpose of the Study:
- To outline the protocol for a randomized controlled trial (I2S2 Trial) on iodine supplementation in preterm infants.
- To assess the impact of iodine supplementation on neurodevelopmental outcomes in this vulnerable population.
Main Methods:
- A randomized controlled trial (I2S2 Trial) protocol is summarized.
- The study focuses on preterm infants receiving parenteral nutrition.
Main Results:
- This section details the study protocol, not yet the results.
- The trial is designed to collect data on neurodevelopmental benefits.
Conclusions:
- The I2S2 Trial aims to provide evidence on the necessity of iodine supplementation for preterm infants.
- Understanding iodine's role in neurodevelopment is critical for optimizing infant nutrition.
Abstract:
This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 microg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.
More Related Videos
10:38Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
Published on: January 16, 2019
07:11Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling
Published on: February 5, 2019
Related Concept Videos
Redox Titration: Iodimetry and Iodometry
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Infants and Children
Bioavailability Study Design: Single Versus Multiple Dose Studies
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview